Sanofi Drops 2.81% Amid Leadership Shakeup

On April 9, 2025, Sanofi's stock experienced a 2.81% drop in pre-market trading, reflecting investor concerns and market sentiment.

Sanofi recently announced a significant leadership change, appointing Feng Ji as the new CEO and Chief Operating Officer. This move replaces Dai Hongbin, who has been promoted to Vice Chairman. Feng Ji brings over two decades of experience in the pharmaceutical industry, having held senior positions at AstraZeneca, Novartis, and Amgen. This change is expected to bring a fresh perspective and strategic direction to Sanofi's operations.

Additionally, Sanofi's pipeline candidate, rilzabrutinib, has received orphan drug designation from the FDA for the treatment of two rare diseases: warm autoimmune hemolytic anemia and IgG4-related disease. This designation is a significant milestone for Sanofi, as it provides incentives for the development of treatments for rare diseases.